Tianda Pharmaceuticals Limited (00455.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 9Sep 14Sep 17

Key dataSep 17, 2026

OpenHKD 0.11

From 52W high−35.67%

Volume16000.00

Market capHKD 236.47M

P/E (TTM)—

P/S (TTM)0.7x

Div yield—

Key dataSep 17, 2026

Open

HKD 0.11

From 52W high

−35.67%

Volume

16000.00

Market cap

HKD 236.47M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.5x

P/E (TTM)

—

RSI (14)

64.8

MomentumView details →

1D Return

−8.33%

YTD Return

−6.98%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−12.5x

EV/Sales

0.9x

P/S (TTM)

0.7x

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

41.28%

Net Margin

−21.67%

EBITDA Margin

−7.56%

ROE (TTM)

−15.33%

ROA (TTM)

−9.36%

Asset Turnover

0.43x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−16.09%

EPS CAGR 3Y

−14.39%

EBITDA YoY

—

MomentumView details →

1D Return

−8.33%

YTD Return

−6.98%

1Y Return

−24.05%

RSI (14)

64.8

vs 50D SMA

+14.05%

vs 200D SMA

+15.98%

Capital & dividendView details →

Debt/Equity

0.29x

Current Ratio

0.83x

Quick Ratio

0.64x

Div Yield

—

Div Rate

—

Div Growth 1Y

+100.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

744.85M

Net Income (TTM)

−118.16M

Op. CF (TTM)

—

Latest newsMore news →

Tianda Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of HK$164 million, up 20.2% year-on-year, net loss narrowed to HK$32.25 million, loss per share of HK$0.015, and no dividend.41d ago

Similar companies

China NT Pharma Group Company Limited01011.HK Aurora Cannabis Inc.ACB Cardiol Therapeutics Inc.CRDL SIGA Technologies, Inc.SIGA Journey Medical CorporationDERM Extrawell Pharmaceutical Holdings Limited00858.HK Find similar companies →

Latest newsMore news →

Tianda Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of HK$164 million, up 20.2% year-on-year, net loss narrowed to HK$32.25 million, loss per share of HK$0.015, and no dividend.41d ago